Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticleAdult Brain

Redefining the Pulvinar Sign in Fabry Disease

S. Cocozza, C. Russo, A. Pisani, G. Olivo, E. Riccio, A. Cervo, G. Pontillo, S. Feriozzi, M. Veroux, Y. Battaglia, D. Concolino, F. Pieruzzi, R. Mignani, P. Borrelli, M. Imbriaco, A. Brunetti, E. Tedeschi and G. Palma
American Journal of Neuroradiology December 2017, 38 (12) 2264-2269; DOI: https://doi.org/10.3174/ajnr.A5420
S. Cocozza
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Cocozza
C. Russo
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Russo
A. Pisani
bPublic Health (A.P., E.R.), Nephrology Unit, University “Federico II,” Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Pisani
G. Olivo
cDepartment of Neuroscience (G.O.), Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Olivo
E. Riccio
bPublic Health (A.P., E.R.), Nephrology Unit, University “Federico II,” Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E. Riccio
A. Cervo
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Cervo
G. Pontillo
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
kInstitute of Biostructure and Bioimaging (G.P.), National Research Council, Naples, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Pontillo
S. Feriozzi
dNephrology and Dialysis Department (S.F.), Belcolle Hospital, Viterbo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Feriozzi
M. Veroux
eDepartment of Medical and Surgical Sciences and Advanced Technologies (M.V.), University Hospital of Catania, Catania, Sicily, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Veroux
Y. Battaglia
fDepartment of Specialized Medicine (Y.B.), Division of Nephrology and Dialysis, St. Anna Hospital-University, Ferrara, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Y. Battaglia
D. Concolino
gDepartment of Pediatrics (D.C.), University Magna Graecia, Catanzaro, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Concolino
F. Pieruzzi
hNephrology Unit (F.P.), University of Milano-Bicocca, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F. Pieruzzi
R. Mignani
iNephrology and Dialysis Department (R.M.), Infermi Hospital, Rimini, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. Mignani
P. Borrelli
jIRCCS SDN (P.B.), Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P. Borrelli
M. Imbriaco
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Imbriaco
A. Brunetti
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Brunetti
E. Tedeschi
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E. Tedeschi
G. Palma
aFrom the Departments of Advanced Biomedical Sciences (S.C., C.R., G.O., A.C., G.P., M.I., A.B., E.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Palma
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: The pulvinar sign refers to exclusive T1WI hyperintensity of the lateral pulvinar. Long considered a common sign of Fabry disease, the pulvinar sign has been reported in many pathologic conditions. The exact incidence of the pulvinar sign has never been tested in representative cohorts of patients with Fabry disease. The aim of this study was to assess the prevalence of the pulvinar sign in Fabry disease by analyzing T1WI in a large Fabry disease cohort, determining whether relaxometry changes could be detected in this region independent of the pulvinar sign positivity.

MATERIALS AND METHODS: We retrospectively analyzed brain MR imaging of 133 patients with Fabry disease recruited through specialized care clinics. A subgroup of 26 patients underwent a scan including 2 FLASH sequences for relaxometry that were compared with MRI scans of 34 healthy controls.

RESULTS: The pulvinar sign was detected in 4 of 133 patients with Fabry disease (3.0%). These 4 subjects were all adult men (4 of 53, 7.5% of the entire male population) with renal failure and under enzyme replacement therapy. When we tested for discrepancies between Fabry disease and healthy controls in quantitative susceptibility mapping and relaxometry maps, no significant difference emerged for any of the tested variables.

CONCLUSIONS: The pulvinar sign has a significantly lower incidence in Fabry disease than previously described. This finding, coupled with a lack of significant differences in quantitative MR imaging, allows hypothesizing that selective involvement of the pulvinar is a rare neuroradiologic sign of Fabry disease.

ABBREVIATIONS:

ERT
enzyme replacement therapy
FD
Fabry disease
HC
healthy controls
PS
pulvinar sign
qMRI
quantitative MRI
QSM
quantitative susceptibility mapping
R1
longitudinal relaxation rate
R2
pure transverse relaxation rate

Fabry disease (FD) is a rare X-linked metabolic disorder caused by insufficient/absent lysosomal α-galactosidase A activity. This enzymatic defect leads to pathologic storage of glycosphingolipids, especially globotriaosylceramide, occurring in all tissues and causing multiorgan progressive dysfunction, in the kidney, heart, and central nervous system.1,2

Neurologic involvement is common in FD.3 Most prominent manifestations include cerebrovascular events, such as transient ischemic attacks and strokes, chronic cerebral vasculopathy, and vessel ectasia, especially in the posterior circulation.4⇓⇓–7 Such clinical manifestations translate, on brain MR imaging, in the presence of white matter hyperintensities3 and increased basilar artery diameter,8,9 both nonspecific for FD.10,11

The pulvinar sign (PS), defined as the exclusive involvement of the lateral pulvinar with symmetric hyperintensity on unenhanced T1-weighted brain MR imaging, has long been considered a common neuroradiologic sign of FD.8,12⇓⇓⇓–16 Originally thought to be pathognomonic of FD,12,13 the PS has actually been reported in other conditions, such as metabolic disorders (eg, Krabbe or Tay-Sachs disease),17,18 CNS infections,19 or after chemoradiation therapy15; therefore, its pathognomonic role has been largely rediscussed.20,21 In fact, the pulvinar nuclei are sensitive to metabolic disturbances, and their MR imaging appearance can be altered in a variety of conditions, especially in patients in whom an abnormal renal function can be a relevant confounding comorbidity.

Moreover, the prevalence of the PS among the FD population has been reconsidered across the years.14–15,22 To date, the exact incidence of the PS has never been tested in a large and representative cohort of patients with FD, because all studies conducted so far were limited to small samples13 or performed only on affected males.12

In this respect, quantitative MR imaging (qMRI) and, in particular, relaxometry are likely to provide unique insight into the pathogenetic mechanisms of the PS. Indeed, a variety of microstructural conditions leading to a shorter longitudinal relaxation rate (R1) (thus, to T1WI hyperintensity) are associated with a faster free induction decay (ie, increase in R2*) and a rise of the pure transverse relaxation rate (R2). As a result, competitive roles of the longitudinal and transverse relaxation rates in MR signal generation suggest that standard evaluations of signal intensity are not the best choice for studying the incidence of PS-associated changes. A thorough relaxometry study would disentangle the contributions of several physical quantities to signal equation of conventional sequences, therefore providing a more accurate indication of the actual PS incidence.

This study has dual aims: 1) to assess the prevalence of PS in a large cohort of subjects with FD by retrospectively analyzing T1WI of 133 patients, and 2) to determine, for the first time, whether relaxometry modifications could be detected in the pulvinar, independent of the PS.

Materials and Methods

Subjects

For the retrospective analysis, in this multicenter study, we analyzed a group of 133 patients with FD (80 women, 60.1%; mean age, 41 ± 13.8 years; age range, 13–73 years) recruited in the previous 5 years through the FD specialized care clinics of 6 different hospitals. Diagnosis of FD was based on reduced plasma levels of α galactosidase A activity of less than average normal values, then confirmed by genotyping tests. Clinical and radiologic data were obtained in different centers as part of the clinical work-up deemed necessary for each patient, and authorization for transfer of data was formerly obtained from the local ethics committee of the coordinating center. Activity of the α galactosidase A enzyme was absent in 42 patients (31.6%), while it showed a residual activity in 91 patients (68.4%); distinct GLA gene mutations were represented, and the clinical manifestations were different, with multiple organ involvement. Finally, 85 patients were treated with enzyme replacement therapy (ERT) (63.9%, with a mean duration of 39.9 ± 61.6 months). Demographic and clinical information of all patients with FD in the retrospective analysis are listed in the On-line Table. For the qMRI analysis, a subgroup of 26 patients with FD (17 women, 65.4%; mean age, 43 ± 12.4 years; age range, 20–68 years) underwent MR imaging at the coordinating center, along with a group of healthy controls (HC) of comparable age and sex, without a history of neurologic, metabolic, or psychiatric disorders. Activity of the α galactosidase A enzyme was absent in 7 patients (26.9%), while it had residual activity in 19 patients (73.1%), with 25 patients treated with ERT (96.2%; mean therapy duration, 43.8 ± 51.2 months). Demographic and clinical information of the qMRI subgroup of patients with FD are also listed in the On-line Table.

This study was performed in accordance with the ethical standards of the Declaration of Helsinki, and written informed consent for the qMRI analysis was preliminarily obtained from the 26 patients with FD and the HC.

Inclusion criteria for patients with FD were the following: genetically proved FD; availability of documentation of brain MR images, including at least 1 spin-echo T1WI sequence independent of the orientations with a section thickness <4 mm; and signed informed consent for participation in the study for subjects undergoing the qMRI analysis. Both adult male and female subjects were approached to participate, without age limitations. Diagnosis of FD was confirmed by biochemical or genetic testing. Indications for brain MR imaging varied between and within centers, including, but not limited to, routine MR imaging, headache, transient neurologic symptoms, and evaluation of an acute cerebrovascular accident. Exclusion criteria for all subjects were evidence of hypo- or hypercalcemia or the presence of any other comorbidity that could have biased the neuroradiologic examination.

From each specialized care center participating in this study, demographic and clinical variables were extracted by a clinician experienced in FD from the medical records or obtained in direct interviews and recorded. These included age recorded at the time of the brain MR imaging, sex, hypertension, diabetes mellitus, cardiac arrhythmia, left ventricular hypertrophy, renal failure (considered present when the estimated glomerular filtration rate of the patient was <90 mL/min), proteinuria (considered present when the patient scored a value >150 mg/24 hours), the presence of neurologic symptoms (including stroke, cephalalgia, acroparesthesia, and so forth), gastrointestinal involvement, renal or cardiac transplant, current use of tobacco or alcohol, as well as treatment with ERT. About 63% of patients with renal failure showed metabolic alterations of parathyroid hormone serum levels attributable to secondary hyperparathyroidism, with no significant derangements of serum calcium levels. Renal function was expressed as the estimated glomerular filtration rate, calculated with the Chronic Kidney Disease Epidemiology Collaboration equation.23 Other laboratory values were measured using standard hospital laboratory techniques. Activity of the α galactosidase A enzyme was reported as “absent” (when showing <1% of normal values) or “residual” (for enzyme activity ranging from 1% to 5% of normal values) because of the different measurement methods used in the recruiting centers (plasma, leukocytes, and so forth).

Each center received a dedicated case report form in which demographic and clinical information were recorded, and then forms were entered into a central data base at the coordinating center according to Good Clinical Practice guidelines.

qMRI Data Acquisition

All studies for the qMRI analysis were performed on the same 3T MR imaging scanner (Magnetom Trio; Siemens, Erlangen, Germany). The acquisition protocol included a dual-echo spoiled gradient-echo (FLASH) sequence (TR = 32 ms, TE1 = 7.38 ms, TE2 = 22.14 ms, flip angle = 20°) and a single-echo FLASH sequence (TR = 16 ms, TE = 7.38 ms, flip angle = 2°). Both sequences were acquired on an FOV of 230 × 194 × 160 mm3, with a voxel size of 0.5 × 0.5 × 1.0 mm3 and a receiver bandwidth of 100 Hz/pixel.

The acquired data were saved as complex datasets reconstructed in magnitude and phase representation for further analyses.

MR Imaging Data Analysis

For the retrospective analysis, MR imaging brain scans were visually assessed by 2 neuroradiologists in consensus, who rated the presence of a clear unilateral or bilateral T1WI hyperintensity at the level of the posterior thalami.

For the qMRI analysis, all magnitude datasets underwent a preliminary multispectral denoising as described in Borrelli et al,24 using a multi-graphics processing unit implementation of the non-local means algorithm previously introduced.25 Quantitative susceptibility mapping (QSM) and R2* maps were derived from the dual-echo FLASH.26 Conversely, given the signal equation of FLASH with FA = θ Embedded Image Embedded Image it can be shown that assuming a T1 > 3 ms, the actual settings of the acquisition parameters (TR = 16 ms, θ1 = 2°, θ2 = 20°) allow R1 computation as Embedded Image where Embedded Image Embedded Image Embedded Image and Embedded Image For each study, 2 irregular bilateral ROIs were hand-drawn in consensus by 2 experienced neuroradiologists on axial sections of the gradient recalled-echo images with the best representation of pulvinar nuclei (Fig 1), according to a human anatomy atlas.27 Mean R1, R2*, and QSM values were automatically obtained from the corresponding maps.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

R1 (A), R2* (B), and QSM (C) maps showing the 2 hand-drawn irregular bilateral ROIs placed in consensus by 2 experienced neuroradiologists on the axial section of the gradient recalled-echo images with the best representation of the pulvinar nuclei.

Statistical Analysis

Statistical analyses were performed with the Statistical Package for the Social Sciences (Version 17.0; IBM, Armonk, New York). An independent 2-sample t test was used for comparing ages and mean values obtained from qMRI analysis, while a χ2 test was used to determine differences in terms of sex. A P = .05 indicated a statistically significant difference. Finally, no Cohen coefficient was needed to evaluate the performance of the evaluation because the 2 neuroradiologists performed the analysis in consensus.

Results

For the retrospective analysis, a clear T1WI hyperintensity of the pulvinar was detected in 4 of 133 patients with FD (3.0%). All 4 patients with positive PSs underwent MR imaging examinations in 2 of the 6 hospitals involved; they all were adult male subjects with an age ranging from 38 to 59 years (mean, 46.5 ± 9.4 years) under ERT and showing signs of renal failure. An example of the PS is shown in Fig 2.

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Unenhanced T1WI axial (A) and sagittal (B) images showing bilateral, symmetric, and well-circumscribed hyperintensity of the pulvinar nuclei in a 47-year-old male patient with FD (A). Axial T2* gradient echo image (C) shows bilateral and symmetric hypointensity corresponding exactly to the T1 hyperintensity, supporting the current hypothesis of focal calcium deposition in both pulvinar nuclei.

For the qMRI analysis, the FD and HC groups were comparable for age and sex. No subject with a positive PS was found in the qMRI subgroup. When we tested for possible differences between these 2 clusters in relaxometry and QSM maps in the FD and HC groups, no significant differences emerged. A complete list of the results obtained by relaxometry and susceptibility analysis, along with the comparison of P values, is shown in the Table.

View this table:
  • View inline
  • View popup

Results of the relaxometry analysisa

Discussion

Our findings support the hypothesis that the true incidence of the PS is considerably lower than previously reported. No significant qMRI differences emerged when testing for possible alterations in subjects without positive PSs, allowing us to speculate that this sign is poorly sensitive for FD.

Exclusive involvement of the lateral pulvinar was first observed by 2 separate groups.12,13 Since then, this sign has been considered as distinctive of FD. Independent from its diagnostic value, the exact incidence of the PS has changed across time,14,15 with a clear downward trend going from 70%13 of earlier studies (though reported in a very small group of patients without any ascertainment data) to complete absence in recent works.20 However, the real incidence of the PS has never been tested in an ample-sized group of patients with FD. Here we expand this knowledge by performing a retrospective analysis of a large and representative population of patients with FD. We observed a prevalence of the PS in FD of 3.0%, significantly lower than previously reported.8,12⇓⇓⇓–16 A possible explanation for this discrepancy could reflect the relatively small sample size of some of the previous studies.15

Nevertheless, when considering the study by Moore et al,12 which included a number of subjects comparable with ours, a higher incidence of the PS was observed. However, the above-mentioned study included only male patients with FD,12 in whom the PS is known to be more frequent,21 and this could have somehow biased the real prevalence of the PS in the global FD population. Supporting this speculation, we were able to replicate such findings when we selected only males with renal function impairment,28 showing a PS prevalence similar to the one reported in Moore et al (4/25, 16.0%).

Another explanation of the previously reported high incidence of a positive PS in patients with FD may be related to possible gadolinium deposition in this structure. Indeed, recent evidence suggests that in subjects with normal renal function receiving multiple contrast administrations, the dentate nuclei and other deep gray matter structures, including the globus pallidus and the pulvinar, could accumulate gadolinium, leading to changes detectable on both conventional and quantitative imaging.29⇓–31 It may, therefore, be hypothesized that the reduced glomerular filtration rate in patients with FD could have influenced the gadolinium clearance, leading to its accumulation in the pulvinar nuclei with subsequent T1WI shortening. However, in patients with FD, T1WI hyperintensity was not observed in the dentate nuclei, which is the preferred site of gadolinium accumulation, and contrast media are rarely administered in these patients, due to their usually impaired renal function. Even though this evidence mitigates the hypothesis of gadolinium accumulation in patients with FD, further properly designed studies may better address the possible relationships between impaired renal function and metal buildup in the pulvinar.

In line with literature data,21 no affected females with the PS were found, considered a rare event16 due to partial/residual enzyme activity. The mean age of our PS-positive patients was 46.5 years, confirming the current hypothesis that the PS could be the neuroradiologic epiphenomenon of a long-term accumulation, whose manifestations only appear progressively.15

Other literature data indicate the poor prognostic value of the PS. Indeed, it has been demonstrated that the PS is somehow independent of major cerebrovascular events, which may occur at any stage of disease.21 Furthermore, no changes in the pulvinar nuclei occurred after long-term ERT, and no association between the PS and a specific genotype has been demonstrated.15

Aside from the incidence of the PS, we aimed to evaluate whether possible changes in susceptibility maps could occur in the pulvinar of patients with FD.

It is widely accepted that the pulvinar is a sensitive region where alterations could develop, independent from the cause. Selective modifications of pulvinar nuclei have been described in other pathologic conditions, such as Wernicke encephalopathy32,33 and Creutzfeldt-Jakob 34,35 and Tay-Sachs diseases.17 In particular, T1WI hyperintensity in the pulvinar has also been described in patients who received chemotherapy/radiation therapy, in patients with neurofibromatosis type 1, and in subjects with Fahr disease or disturbances of the calcium-phosphorus metabolism or even laminar necrosis.36⇓–38

To date, the real pathogenesis of the PS in FD is still unclear. The most reliable hypothesis is the development of subtle dystrophic calcification, confirmed by CT brain scans, probably related to chronic hypoperfusion secondary to microvascular alterations.6,14,39⇓–41 These alterations have been reported not only in the pulvinar but also in other deep gray nuclei such as the globus pallidus, even if in a lower percentage of cases.12⇓–14

Quantitative MR imaging can allow early detection of changes not appreciable on conventional MR images,42 possibly providing additional information in understanding PS physiopathology. However, we found no differences in the pulvinar in any of the examined qMRI maps of patients with FD compared with HC. This absence of significant differences, however, should not lead to the superficial deduction that the PS is not linked to abnormal mineral deposition. Unfortunately, in our qMRI FD subgroup, no subjects with clear PSs were present because of the low incidence of this sign. On the other hand, in patients positive for the PS, a clinical T2*WI FLASH sequence was available and showed clear hypointensity corresponding to T1WI hyperintensity, corroborating the current hypothesis of calcium deposition in the posterior thalami when the PS is present. A possible explanation for the absence of sensitive mineralization in the PS-negative group might be related to the ongoing therapy, since the FD subgroup with available qMRI sequences almost entirely consisted of subjects under ERT (25/26 patients). Indeed, due to the current pathogenetic assumption that microvascular changes are responsible for PS development, it can be hypothesized that early diagnosis of FD, coupled with the availability of effective treatment options, could have directly or indirectly improved local microvascular homeostasis. Nonetheless, this speculation should be corroborated by further longitudinal evaluations of qMRI, to clarify the relationship between these measures and ERT.

Conclusions

We showed a significantly lower incidence (only 3%) of the PS in FD compared with what has been previously described, coupled with no significant qMRI differences in these regions between those with FD and HC. Our results, taken together, allow hypothesizing that selective pulvinar involvement with well-circumscribed T1-hyperintensity, though easy to identify, is a rare neuroradiologic sign whose presence is detectable in only a few exceptional cases of FD. Moreover, because this finding has also been reported in other conditions of metabolic dysfunction, it should not be considered specifically related to globotriaosylceramide accumulation and its role as a sensitive sign of this disease should be reconsidered.

Footnotes

  • Sirio Cocozza and Camilla Russo contributed equally to this work.

  • Enrico Tedeschi and Giuseppe Palma share senior authorship.

  • Disclosures: Sirio Cocozza—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme. Antoni Pisani—UNRELATED: Consultancy: Genzyme, Shire, Amicus; Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire, Amicus; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire, Amicus. Eleonora Riccio—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire. Daniela Concolino—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Shire; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Shire. Federico Pieruzzi—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire, Amicus; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire, Amicus. Sandro Feriozzi—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire. Renzo Mignani—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire. Massimiliano Veroux—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme, Shire; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme, Shire. Yuri Battaglia—UNRELATED: Payment for Lectures Including Service on Speakers Bureaus: Genzyme; Travel/Accommodations/Meeting Expenses unrelated to Activities Listed: Genzyme.

References

  1. 1.↵
    1. Eng CM,
    2. Germain DP,
    3. Banikazemi M, et al
    . Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539–48 doi:10.1097/01.gim.0000237866.70357.c6 pmid:16980809
    CrossRefPubMed
  2. 2.↵
    1. Germain DP
    . Fabry disease. Orphanet J Rare Dis 2010;5:30 doi:10.1186/1750-1172-5-30 pmid:21092187
    CrossRefPubMed
  3. 3.↵
    1. Buechner S,
    2. Moretti M,
    3. Burlina AP, et al
    . Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1249–54 doi:10.1136/jnnp.2008.143693 pmid:18535022
    Abstract/FREE Full Text
  4. 4.↵
    1. Kaye EM,
    2. Kolodny EH,
    3. Logigian EL, et al
    . Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23:505–09 doi:10.1002/ana.410230513 pmid:3133979
    CrossRefPubMed
  5. 5.↵
    1. Mitsias P,
    2. Levine SR
    . Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8–17 doi:10.1002/ana.410400105 pmid:8687196
    CrossRefPubMed
  6. 6.↵
    1. Moore DF,
    2. Kaneski CR,
    3. Askari H, et al
    . The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007;257:258–63 doi:10.1016/j.jns.2007.01.053 pmid:17362993
    CrossRefPubMed
  7. 7.↵
    1. Fellgiebel A,
    2. Keller I,
    3. Marin D, et al
    . Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009;72:63–68 doi:10.1212/01.wnl.0000338566.54190.8a pmid:19122032
    CrossRefPubMed
  8. 8.↵
    1. Fellgiebel A,
    2. Keller I,
    3. Martus P, et al
    . Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011;31:294–99 doi:10.1159/000322558 pmid:21196729
    CrossRefPubMed
  9. 9.↵
    1. Manara R,
    2. Carlier RY,
    3. Righetto S, et al
    . Basilar artery changes in Fabry disease. AJNR Am J Neuroradiol 2017;38:531–36 doi:10.3174/ajnr.A5069 pmid:28126747
    Abstract/FREE Full Text
  10. 10.↵
    1. Putaala J,
    2. Kurkinen M,
    3. Tarvos V, et al
    . Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke. Neurology 2009;72:1823–29 doi:10.1212/WNL.0b013e3181a711df pmid:19470964
    Abstract/FREE Full Text
  11. 11.↵
    1. Uçeyler N,
    2. Homola GA,
    3. Guerrero González H, et al
    . Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One 2014;9:e87054 doi:10.1371/journal.pone.0087054 pmid:24475221
    CrossRefPubMed
  12. 12.↵
    1. Moore DF,
    2. Ye F,
    3. Schiffmann R, et al
    . Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003;24:1096–101 pmid:12812932
    Abstract/FREE Full Text
  13. 13.↵
    1. Takanashi J,
    2. Barkovich AJ,
    3. Dillon WP, et al
    . T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 2003;24:916–21 pmid:12748094
    Abstract/FREE Full Text
  14. 14.↵
    1. Fellgiebel A,
    2. Mazanek M,
    3. Whybra C, et al
    . Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study. J Neurol 2006;253:780–87 doi:10.1007/s00415-006-0118-y pmid:16511647
    CrossRefPubMed
  15. 15.↵
    1. Burlina AP,
    2. Manara R,
    3. Caillaud C, et al
    . The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 2008;255:738–44 doi:10.1007/s00415-008-0786-x pmid:18297328
    CrossRefPubMed
  16. 16.↵
    1. Burlina AP,
    2. Politei J,
    3. Cinque S, et al
    . The pulvinar sign in Fabry patients: the first report in female patients. J Neurol 2012;259:1227–28 doi:10.1007/s00415-011-6305-5 pmid:22095041
    CrossRefPubMed
  17. 17.↵
    1. Mugikura S,
    2. Takahashi S,
    3. Higano S, et al
    . MR findings in Tay-Sachs disease. J Comput Assist Tomogr 1996;20:551–55 doi:10.1097/00004728-199607000-00009 pmid:8708054
    CrossRefPubMed
  18. 18.↵
    1. Kendall BE
    . Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol 1992;13:621–53 pmid:1566722
    FREE Full Text
  19. 19.↵
    1. Sahraian MA,
    2. Motamedi M,
    3. Azimi AR, et al
    . Bilateral pulvinar thalamic calcification in a patient with chronic cryptococcal meningitis. Eur J Neurol 2007;14:e1–2 pmid:17388969
    CrossRefPubMed
  20. 20.↵
    1. Fazekas F,
    2. Enzinger C,
    3. Schmidt R, et al
    ; SIFAP 1 Investigators. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke 2015;46:1548–53 doi:10.1161/STROKEAHA.114.008548 pmid:25899239
    Abstract/FREE Full Text
  21. 21.↵
    1. Kolodny E,
    2. Fellgiebel A,
    3. Hilz MJ, et al
    . Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015;46:302–13 doi:10.1161/STROKEAHA.114.006283 pmid:25492902
    FREE Full Text
  22. 22.↵
    1. Lee HJ,
    2. Hsu TR,
    3. Hung SC, et al
    . A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. BMC Neurol 2017;17:25 doi:10.1186/s12883-017-0810-9 pmid:28166746
    CrossRefPubMed
  23. 23.↵
    1. Vučić Lovrenčić M,
    2. Radišić Biljak V,
    3. Božičević S, et al
    . Estimating glomerular filtration rate (GFR) in diabetes: the performance of MDRD and CKD-EPI equations in patients with various degrees of albuminuria. Clin Biochem 2012;45:1694–96 doi:10.1016/j.clinbiochem.2012.07.115 pmid:22968085
    CrossRefPubMed
  24. 24.↵
    1. Borrelli P,
    2. Palma G,
    3. Tedeschi E, et al
    . Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach. PLoS One 2015;10:e0126835 doi:10.1371/journal.pone.0126835 pmid:26030293
    CrossRefPubMed
  25. 25.↵
    1. Palma G,
    2. Comerci M,
    3. Alfano B, et al
    . 3D non-local means denoising via multi-GPU. Fed Conf Comput Sci 2013:495–98
  26. 26.↵
    1. Palma G,
    2. Tedeschi E,
    3. Borrelli P, et al
    . A novel multiparametric approach to 3D quantitative MRI of the brain. PLoS One 2015;10:e0134963 doi:10.1371/journal.pone.0134963 pmid:26284778
    CrossRefPubMed
  27. 27.↵
    1. Schaltenbrand G,
    2. Wahren W
    . Atlas for Stereotaxy of the Human Brain. 2nd ed. Stuttgart: Thieme; 1977
  28. 28.↵
    1. Branton M,
    2. Schiffmann R,
    3. Kopp JB
    . Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S139–43 pmid:12068026
    FREE Full Text
  29. 29.↵
    1. Kanda T,
    2. Ishii K,
    3. Kawaguchi H, et al
    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844
    CrossRefPubMed
  30. 30.↵
    1. Ramalho J,
    2. Semelka RC,
    3. Ramalho M, et al
    . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341
    Abstract/FREE Full Text
  31. 31.↵
    1. Tedeschi E,
    2. Palma G,
    3. Canna A, et al
    . In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol 2016;26:4577–84 doi:10.1007/s00330-016-4245-2 pmid:26905870
    CrossRefPubMed
  32. 32.↵
    1. Torvik A,
    2. Lindboe CF,
    3. Rogde S
    . Brain lesions in alcoholics: a neuropathological study with clinical correlations. J Neurol Sci 1982;56:233–48 doi:10.1016/0022-510X(82)90145-9 pmid:7175549
    CrossRefPubMed
  33. 33.↵
    1. Antunez E,
    2. Estruch R,
    3. Cardenal C, et al
    . Usefulness of CT and MR imaging in the diagnosis of acute Wernicke's encephalopathy. AJR Am J Roentgenol 1998;171:1131–37 doi:10.2214/ajr.171.4.9763009 pmid:9763009
    CrossRefPubMed
  34. 34.↵
    1. Zeidler M,
    2. Sellar RJ,
    3. Collie DA, et al
    . The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1412–18 doi:10.1016/S0140-6736(00)02140-1 pmid:10791525
    CrossRefPubMed
  35. 35.↵
    1. Keohane C
    . Pulvinar sign on MRI images in variant Creutzfeldt-Jakob disease. Lancet 2000;355:1384 doi:10.1016/S0140-6736(00)02133-4 pmid:10791518
    CrossRefPubMed
  36. 36.↵
    1. Ginat DT,
    2. Meyers SP
    . Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis. Radiographics 2012;32:499–516 doi:10.1148/rg.322105761 pmid:22411945
    CrossRefPubMed
  37. 37.↵
    1. Renard D,
    2. Castelnovo G,
    3. Campello C, et al
    . Thalamic lesions: a radiological review. Behav Neurol 2014;2014:154631 doi:10.1155/2014/154631 pmid:25100900
    CrossRefPubMed
  38. 38.↵
    1. Zaitout Z,
    2. Romanowski C,
    3. Karunasaagarar K, et al
    . A review of pathologies associated with high T1W signal intensity in the basal ganglia on magnetic resonance imaging. Pol J Radiol 2014;79:126–30 doi:10.12659/PJR.890043 pmid:24900164
    CrossRefPubMed
  39. 39.↵
    1. Moore DF,
    2. Altarescu G,
    3. Barker WC, et al
    . White matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231–40 doi:10.1016/j.brainresbull.2003.09.021 pmid:14698356
    CrossRefPubMed
  40. 40.↵
    1. Igarashi T,
    2. Sakuraba H,
    3. Suzuki Y
    . Activation of platelet function in Fabry's disease. Am J Hematol 1986;22:63–67 doi:10.1002/ajh.2830220110 pmid:3006478
    CrossRefPubMed
  41. 41.↵
    1. DeGraba T,
    2. Azhar S,
    3. Dignat-George F, et al
    . Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229–33 pmid:10665494
    CrossRefPubMed
  42. 42.↵
    1. Deoni SC
    . Quantitative relaxometry of the brain. Top Magn Reson Imaging 2010;21:101–13 doi:10.1097/RMR.0b013e31821e56d8 pmid:21613875
    CrossRefPubMed
  • Received March 30, 2017.
  • Accepted after revision July 22, 2017.
  • © 2017 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 38 (12)
American Journal of Neuroradiology
Vol. 38, Issue 12
1 Dec 2017
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Redefining the Pulvinar Sign in Fabry Disease
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Redefining the Pulvinar Sign in Fabry Disease
S. Cocozza, C. Russo, A. Pisani, G. Olivo, E. Riccio, A. Cervo, G. Pontillo, S. Feriozzi, M. Veroux, Y. Battaglia, D. Concolino, F. Pieruzzi, R. Mignani, P. Borrelli, M. Imbriaco, A. Brunetti, E. Tedeschi, G. Palma
American Journal of Neuroradiology Dec 2017, 38 (12) 2264-2269; DOI: 10.3174/ajnr.A5420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Redefining the Pulvinar Sign in Fabry Disease
S. Cocozza, C. Russo, A. Pisani, G. Olivo, E. Riccio, A. Cervo, G. Pontillo, S. Feriozzi, M. Veroux, Y. Battaglia, D. Concolino, F. Pieruzzi, R. Mignani, P. Borrelli, M. Imbriaco, A. Brunetti, E. Tedeschi, G. Palma
American Journal of Neuroradiology Dec 2017, 38 (12) 2264-2269; DOI: 10.3174/ajnr.A5420
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Clinical Profiles and Patterns of Neurodegeneration in Amyotrophic Lateral Sclerosis: A Cluster-Based Approach Based on MR Imaging Metrics
  • Comparison between Dual-Energy CT and Quantitative Susceptibility Mapping in Assessing Brain Iron Deposition in Parkinson Disease
  • Incidental Findings from 16,400 Brain MRI Examinations of Research Volunteers
Show more ADULT BRAIN

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire